8-K: Moleculin Biotech Announces Full Year 2024 Financial Results and Provides Corporate Update

Moleculin Biotech reports its full year 2024 financial results and provides a corporate update, highlighting progress in its Phase 3 MIRACLE trial and expected data readouts.

Summary

• Moleculin Biotech announced its financial results for the year ended December 31, 2024, and provided a corporate update on March 24, 2025.
• The company is making progress in its pivotal, adaptive Phase 3 MIRACLE trial, with the first subject treatment expected in the first quarter of 2025.
• Multiple subjects are currently being screened at the first MIRACLE site.
• Initial data readout from the Phase 3 MIRACLE trial is expected in the second half of 2025.
• The company received positive FDA guidance for accelerating the MIRACLE trial, resulting in a smaller number of subjects.
• The company expects to unblind preliminary data from the first 45 subjects in the second half of 2025.
• The company expects to reach the second unblinding (75-90 subjects) in the first half of 2026.
• Research and development expenses were $17.7 million for 2024, compared to $19.5 million in 2023.
• General and administrative expenses were $8.8 million for 2024, compared to $10.0 million in 2023.
• As of December 31, 2024, the company had cash and cash equivalents of $4.3 million.
• The company believes its existing cash and the $9.3 million from February 2025 financing will fund operations into the third quarter of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is making progress in its clinical trials and has received positive feedback from the FDA. However, the company's cash position is a concern, and it will need to raise additional capital to continue its operations.

Positives

• The company is making progress in its Phase 3 MIRACLE trial for R/R AML.
• The FDA provided positive guidance, allowing for a smaller number of subjects in the MIRACLE trial.
• The company received its first country regulatory approval in Europe to begin enrolling for the MIRACLE trial.
• New preclinical findings demonstrate significant activity of Annamycin in Venetoclax resistant AML model.
• The company has expanded global exclusivity for Annamycin with Notice of Intent to Grant for the European patent application.
• The company has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for the treatment of soft tissue sarcoma.
• Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the European Medicines Agency (EMA).

Negatives

• The company had cash and cash equivalents of $4.3 million as of December 31, 2024, which may require additional financing in the future.
• The company believes its existing cash and the $9.3 million from February 2025 financing will fund operations only into the third quarter of 2025.

Risks

• The company will require significant additional financing to conduct its clinical trials.
• The milestones described assume the company's ability to secure such financing on a timely basis.
• The MIRACLE study is subject to appropriate future filings with and potential additional feedback from the FDA and their foreign equivalents.

Future Outlook

The company anticipates an exciting year with potential value-driving milestones and expects to unblind preliminary data from the first 45 subjects in the second half of 2025.

Management Comments

• Walter Klemp, Chairman and Chief Executive Officer of Moleculin, stated that the last year was a very productive and substantial year for Moleculin.
• Walter Klemp believes that they continue to successfully execute on activities for their MIRACLE trial, supported by a growing body of positive preliminary data and encouraging interactions with FDA and clinical sites.
• Walter Klemp looks forward to an exciting year with a number of potential value-driving milestones expected in the coming months.
• Walter Klemp stated that with the clinical and regulatory progress made to date, they still expect to unblind preliminary data from the first 45 subjects in the second half of this year.
• Walter Klemp's team is dedicated to advancing the development of Annamycin and they look forward to providing additional updates.

Industry Context

Moleculin Biotech is focused on developing therapies for hard-to-treat cancers and viruses, a space with significant unmet medical need and potential for high reward. The company's lead program, Annamycin, targets relapsed or refractory AML, a challenging disease with limited treatment options.

Comparison to Industry Standards

• Many companies are developing therapies for AML, including established pharmaceutical companies and smaller biotech firms.
• Notable competitors include Agios Pharmaceuticals with Tibsovo, and Servier Pharmaceuticals with Asparlas.
• Moleculin's Annamycin aims to differentiate itself by addressing multidrug resistance and reducing cardiotoxicity, common issues with existing anthracyclines.
• The MIRACLE trial's adaptive design and focus on a specific patient population (R/R AML) are consistent with current trends in clinical trial design to improve efficiency and increase the likelihood of success.

Stakeholder Impact

• Shareholders: The progress in clinical trials and potential for regulatory approval could positively impact shareholder value.
• Employees: Continued funding and progress in development programs provide job security and opportunities for growth.
• Patients: Successful development of Annamycin could provide a new treatment option for patients with R/R AML and STS lung metastases.
• Investors: The company's need for additional financing could lead to dilution of existing shareholders.

Next Steps

• The company expects to treat the first subject in the MIRACLE trial in the first quarter of 2025.
• The company expects an initial data readout from the MIRACLE trial in the second half of 2025.
• The company will continue to enroll subjects in the MIRACLE trial.
• The company will identify the next phase of development / pivotal IIT (investigator-initiated-trial) program for Annamycin STS Lung Mets Development Program.

Key Dates

Keywords

Annamycin, MIRACLE trial, Acute Myeloid Leukemia, AML, Moleculin Biotech, R/R AML, Clinical Trial, Financial Results